We believe our MultiStem cell therapy represents a potential breakthrough in the field of regenerative medicine and stem cell therapy and could be used to treat a range of disease indications. These represent major areas of clinical need, as well as substantial commercial opportunities. Our current clinical development programs are focused on treating critical care and other conditions where current standard of care is limited or inadequate for many patients. Our most advanced program is focused on the treatment of ischemic stroke, which is currently being evaluated in a registrational trial in Japan, and an ongoing Phase 3 clinical trial in North America under a Special Protocol Assessment, or SPA, and Europe. Our MultiStem ® cell therapy, a patented and proprietary allogeneic stem cell product, is our lead platform product and is currently in clinical development. We are committed to the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life and have established a portfolio of therapeutic product development programs to address significant unmet medical needs in multiple disease areas. We are an international biotechnology company that is focused primarily in the field of regenerative medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |